Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study

(2018) Daniel Millard et al.   TOXICOLOGICAL SCIENCES

A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes

(2017) Hiroyuki Ando et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment

(2017) Kelly C. Chang et al.   Frontiers in Physiology

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

(2017) Sara Dutta et al.   Frontiers in Physiology

Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias

(2016) Ksenia Blinova et al.   TOXICOLOGICAL SCIENCES

Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial

(2015) L Johannesen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Differentiating Drug-Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and Verapamil

(2014) L Johannesen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium

(2013) Philip T. Sager et al.   AMERICAN HEART JOURNAL

Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science

(2013) L Johannesen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS